

- institutions for, 8
 interstitial lung diseases, 1716
 iodine deficiency, 2285, 2285f
 iron-deficiency anemia, 626
 ischemic heart disease, 1578
 jaundice, 285
K. pneumoniae infections, 1031–1032
 kidney disease, 1799, 1862–1863
 laryngitis, 234
Legionella spp. infections, 1014, 1015
 leprosy, 1123, 1124, 2684
 leptospirosis, 1141
 liver abscess, 850
 Lyme borreliosis, 1151
 lymphatic filariasis, 1417, 1420
 lymphogranuloma venereum, 1169
 lyssaviruses, 1304
M. pneumoniae infections, 1164
 malaria, 14–15, 151e-4, 1370–1371, 1370f
 mastoiditis, 230
 maternal mortality, 51
 measles, 1295
 Mediterranean spotted fever, 1157
 meningococcal disease, 995–996, 997f
 meningococcal vaccines, 1001, 1002
 meningococcemia, 781–782
 mental disorders, 17, 2708
 Mesoamerican nephropathy, 1855–1856
 monkeypox, 220e-1–2
 MRSA infections, 918
 multiple myeloma, 713
 mumps, 231e-1, 231e-1f, 231e-3
 neurologic disease, 2535, 2535t
 nocardiosis, 1084
 noma, 1097
 nonalcoholic fatty liver disease, 2057
 nontuberculous mycobacterial infections, 1128–1129, 1132
 nontyphoidal *Salmonella* infections, 1053
 norovirus infections, 1285
 nutritional issues, 461
 obesity, 17, 266e-4
 opioid use disorders, 468e-1
 osteoarthritis, 2228
P. aeruginosa infections, 1043, 1045
 Paget's disease of bone, 426e-1
 parenteral nutrition, 98e-9
 parvovirus B19 infections, 1196
 PCP pneumonia, 1358
 pellagra, 2690
 peptic ulcer disease, 1042
 pertussis, 1021, 1021f, 1024
 plague, 1070–1071, 1071f, 1073
 pneumococcal infections, 949
 pneumococcal vaccine, 947
 poliovirus infections, 896, 1294, 1294t
 porphyrias, 2521, 2531
 prion diseases, 453e-1–2, 453e-1t
 pulmonary infiltrates with eosinophilia, 1687
 pulmonary paragonimiasis, 245
 Q fever, 1161
 rabies, 1300
 relapsing fever, 1146
 rheumatic fever, 2149
 rheumatic heart disease, 964f, 1501, 1528–1529, 2149
 rheumatoid arthritis, 1304, 2139, 2139f, 2149
 rickettsial diseases, 782, 1157
 Rocky Mountain spotted fever, 1154
 rotavirus infections, 1287, 1288f, 1289
 rubella, 230e-1, 230e-2–3, 230e-3f
 sarcoidosis, 2205
 schistosomiasis, 1424, 1425, 1425f
 scrub typhus, 1159
 selenium deficiency, 96e-10
 sexually transmitted infections, 869, 879
Shigella infections, 1055, 1057
 sleeping sickness, 1397
 snakebite care, 2738
Spirillum infection, 167e-2
 syphilis, 1133
 systemic lupus erythematosus, 2134
T. cruzi infections, 1396
T. gondii infections, 1404
 tapeworm infections, 1430
 testicular cancer, 588
 tetanus, 984, 986–987
 tobacco use, 17
 trachoma, 1172
 travel medicine, 793, 855
 trematode infections, 1424
 trichinellosis, 1410
 tropical pulmonary eosinophilia, 1420
 tropical sprue, 1942
 tuberculosis, 12–13, 205e-1, 778, 1103–1105, 1104f
 tularemia, 1067
 urinary tract infections, 862, 866
 vaccine-preventable disease, 785, 786
 valvular heart disease, 1528–1529
 vancomycin resistance rates, 973
Vibrio spp. infections, 1065, 1065t
 viral arthritis, 837
 viral hemorrhagic fevers, 782–783
 vitamin A deficiency, 96e-6
 vitamin D deficiency, 315
 Whipple's disease, 1091
 Wilson's disease, 2521
Yersinia spp. infections, 1076, 1077, 1078
 Global health equity, 10, 13e-4–5, 17
 Global Health Initiative, 13e-8
 Global Malaria Action Plan (GMAP), 14
 Globi, 1124
 Globin genes, 631, 631f, 632–633
 Globus pharyngeus, 254
 Globus sensation, 1901
 Glomerular diseases, **1831**. *See also specific diseases*
 acute nephritic syndromes. *See* Acute nephritic syndromes
 approach to the patient, 1834–1836, 1834t
 basement membrane syndromes. *See* Basement membrane syndromes
 clinical syndromes, 1835–1836, 1835–1836t
 genetic considerations in, 1832
 glomerular-vascular syndromes, 1835t, 1836, 1847–1848
 glomerulonephritis. *See* Glomerulonephritis
 hematuria in, 294, 1834, 1835t
 infectious disease-associated syndromes, 1836, 1836t, 1848–1850
 microalbuminuria in, 1834t
 nephrotic syndromes. *See* Nephrotic syndromes
 pathogenesis of, 1832–1834, 1833f
 progression of, 1834
 proteinuria in, 1834, 1834t, 1835t
 pulmonary-renal syndromes, 1835t, 1836, 1846
 renal biopsy in, 62e-1–6f, 1836–1837
 Glomerular filtration rate (GFR)
 age-related decline in, 1812
 assessment of, 290–291, 1812, 1813t
 in kidney disease, 290–291
 in pregnancy, 46
 reduced, 290–291
 regulation of, 332e-2–3, 1800, 1801f
 serum creatinine and, 290–291
 Glomerulonephritis
 acute, 1806t, 1836
 C3, 62e-4f
 chronic, 1836
 classification of, 1836–1837
 endocarditis-associated, 1835t, 1837–1838
 hematuria in, 294, 1834
 membranoproliferative. *See* Membranoproliferative glomerulonephritis
 membranous. *See* Membranous glomerulonephritis
 mesangioproliferative, 1835t, 1841
 pathogenesis of, 1832–1833
 pauci-immune, 1840
 poststreptococcal. *See* Poststreptococcal glomerulonephritis
 progression of, 62e-9–10f, 1834
 rapidly progressive (crescentic), 1836, 1846f
 in relapsing polychondritis, 2204
 renal biopsy in, 62e-1–6f, 1836–1837
 in Sjögren's syndrome, 2167
 in SLE. *See* Lupus nephritis
 tubulointerstitial abnormalities with, 1860–1861
 Glomerulosclerosis
 age-related, 1837
 focal segmental. *See* Focal segmental glomerulosclerosis
 Glomerulus (glomeruli)
 anatomy of, 1812f, 1831–1832, 1832f
 embryologic development of, 332e-1
 filtration by, 333e-1
 histology of, 1813f
 Glossitis, 241t, 463t, 1946t
 Glossodynia (burning mouth syndrome; glossalgia), 215, 239
 Glossopharyngeal nerve, 213, 213f, 2538
 Glossopharyngeal neuralgia, 237, 2649, 2664
 GLP-1. *See* Glucagon-like peptide-1 (GLP-1)
 Glucagon
 for bradycardia due to poisoning/overdose, 473e-9t
 for food impaction dislodgement, 1911
 in hypoglycemia, 2431t
 in shock, 1745
 Glucagon cell adenomatosis, 569
 Glucagon-like peptide-1 (GLP-1), 559t, 572, 2402
 Glucagon-like peptide-1 (GLP-1) receptor agonists, 2414t, 2416
 Glucagonoma, **569**
 clinical features of, 559t, 569, 2338
 diagnosis of, 570
 incidence of, 561
 in MEN 1, 2338
 skin manifestations of, 356t
 treatment of, 570, 2338
 Glucocorticoid(s)
 for ACTH deficiency, 2260
 actions of, 1829t
 for adrenal insufficiency, 2325–2326
 adverse effects of, 598, 1677, 1831, 2130t, 2667
 carcinogenicity, 477t
 cataracts, 204
 cutaneous, 352, 356, 379, 381, 732
 depression, 63
 edema, 253t
 eosinopenia, 423
 hypertrichosis, 380
 late, 620t
 major, 2182t
 in myocardial infarction, 1604
 myopathy, 462e-19–20, 462e-20t, 2199, 2218t
 osteoporosis, 2492, 2503–2504
 in pregnancy, 373
 protection from, 622, 2667
 psychosis, 2129
 for alcoholic liver disease, 2053, 2054f, 2059
 for allergic conjunctivitis, 199
 for anaphylaxis, 2117
 for angioedema, 2119–2120
 for anterior ischemic optic neuropathy, 202
 for autoimmune hemolytic anemia, 658
 for autoimmune hepatitis, 2051–2052
 for autoimmune pancreatitis, 2099
 for Behçet's syndrome, 2194
 for bronchiectasis, 1696
 for CAH, 2328–2329
 for cancer, 103e-15
 for cerebellar degeneration, 618
 for chronic inflammatory demyelinating neuropathy, 2699
 for cluster headache prevention, 2595, 2595t
 for contact dermatitis, 354t
 diabetes mellitus and, 2421–2422
 drug interactions of, 2130t
 for dyspnea, 62
 for ectopic ACTH syndrome, 611
 for eosinophilia, 613
 for eosinophilic granulomatosis with polyangiitis, 1685, 1686, 2187
 epidural, for back pain, 120